September 24, 2012
by admin
6 Comments
The pharma industry, with decadal time lines and multi-billion dollar R&D budgets, is particularly sensitive to progressing projects that should have been killed. Occasionally failure is perfectly obvious, and the decision to kill a project is trivial. But much more … Continue reading
September 7, 2012
by admin
3 Comments
The future of the pharmaceutical industry depends on improving our approach to the early Phase 2 trials. After all, three of the most important decisions relating to a drug product candidate are founded on the data emerging from Phase 2a … Continue reading